Cellular stress response and apoptosis in cancer therapy

Blood

Volumn 98, Issue 9, 2001, Pages 2603-2614

  Herr, Ingrid ^a,b   Debatin, Klaus Michael ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INDUCING FACTOR; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE; CASPASE 8; CELL RECEPTOR; CERAMIDE; CHAPERONE; CYTOCHROME C; CYTOKINE; CYTOTOXIC AGENT; FAS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; PROTEIN P53; SPHINGOMYELIN;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CYTOKINE PRODUCTION; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN INDUCTION; REVIEW; SIGNAL TRANSDUCTION; STRESS;

EID: 0035525733     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.9.2603     Document Type: Review

References (232)

1. Steller H. Mechanisms and genes of cellular suicide. Science. 1995;267:1445-1449.
2. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1985;267:1456-1462.
3. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell. 1994;78:539-542.
4. Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res. 1989;49:5870-5878.
5. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770-776.
6. Nagata S. Apoptotic DNA fragmentation. Exp Cell Res. 2000;256:12-18.
7. Stegh AH, Herrmann H, Lampel S, et al. Identification of the cytolinker plectin as a major early in vivo substrate for caspase-8 during CD95- and tumor necrosis factor receptor-mediated apoptosis. Mol Cell Biol. 2000;20:5665-5679.
8. Green D, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309-1312.
9. Krammer PH. CD95's deadly mission in the immune system. Nature. 2000;407:789-795.
10. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med. 2000;6:513-519.
11. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol. 1999;11:68-75.
12. Antonsson B, Martinou J-C. The Bcl-2 protein family. Exp Cell Res. 2000;256:50-57.
13. Guo B, Godzik A, Reed JC. Bcl-G, a novel proapoptotic member of the Bcl-2 family. J Biol Chem. 2001;276:2780-2785.
14. Ke N, Godzik A, Reed JC. Bcl-B, a novel Bcl-2 family member that differentially binds and regulates Bax and Bak. J Biol Chem. 2001;276:12481-12484.
15. Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288:1053-1058.
16. L can confer a multidrug resistance phenotype. Blood. 1995;86:1903-1910.
17. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science. 2000;290:989-992.
18. Campos L, Rouault JP, Sabido O, et al. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993;81:3091-3096.
19. Nagata S. Apoptosis by death factor. Cell. 1997;88:355-365.
20. Zhang H, Xu Q, Krajewski S, et al. BAR: an apoptosis regulator at the intersection of caspases and Bcl-2 family proteins. Proc Natl Acad Sci U S A. 2000;97:2597-2602.
21. L- and procaspase-8-associated protein in the endoplasmic reticulum. J Cell Biol. 1997;139:327-338.
22. Kataoka T, Schröter M, Hahne M, et al. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and γ irradiation. J Immunol. 1998;161:3936-3942.
23. Krammer PH. CD95(APO-1/Fas)-mediated apoptosis: live and let die. Adv Immunol. 1999;71:163-210.
24. Pitti RM, Marsters SA, Lawrence DA, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 1998;396:699-703.
25. Deveraux QL, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev. 1999;13:239-252.
26. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997;388:300-304.
27. Los M, Wesselborg S, Schulze-Osthoff KM. The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. Immunity. 1999;10:629-639.
28. Uren AG, Coulson EJ, Vaux DL. Conservation of baculovirus inhibitor of apoptosis repeat proteins (BIRPs) in viruses, nematodes, vertebrates and yeasts. Trends Biochem Sci. 1998;23:159-162.
29. Fesik SW. Insights into programmed cell death through structural biology. Cell. 2000;103:273-282.
30. Kasof GK, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem. 2001;276:3238-3246.
31. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol. 2000;10:1359-1366.
32. Debatin K-M. Disturbances of the CD95 (APO-1/Fas) system in disorders of lymphohematopoietic cells. Cell Death Differ. 1996;3:185-189.
33. Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81:935-946.
34. Lynch DH, Watson ML, Alderson MR, et al. The mouse fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity. 1994;1:131-136.
35. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268:1347-1349.
36. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 1994;76:969-976.
37. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356:314-317.
38. Reap EA, Roof K, Maynor K, Cohen PL. Markedly diminished radiation-induced lymphocyte apoptosis in lpr mice suggests a role for Fas in eliminating damaged cells. Ann N Y Acad Sci. 1997;5:116-118.
39. Belka C, Marini P, Budach W, et al. Radiation-induced apoptosis in human lymphocytes relies on the up-regulation of CD95/Fas/APO-1 ligand. Radiat Res. 1998;149:588-595.
40. Bernassola F, Scheuerpflug C, Herr I, Krammer PH, Debatin K-M, Melino G. Induction of apoptosis by IFNg in human neuroblastoma cell lines through the CD95/CD95L autocrine circuit. Cell Death Differ. 1999;6:652-660.
41. Caricchio R, Kovalenko D, Kaufmann WK, Cohen P. Apoptosis provoked by the oxidative stress inducer menadione (vitamin K3) is mediated by the Fas/Fas ligand system. Clin Immunol. 1999;93:65-74.
42. Caricchio R, Reap E, Cohen P. Fas/Fas ligand interactions are involved in UV-B-induced human lymphocyte apoptosis. J Immunol. 1998;161:241-251.
43. Friesen C, Herr I, Krammer PH, Debatin K-M. Involvement of the CD95 (APO-1/Fas) receptor ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 1996;2:574-577.
44. Fulda S, Los M, Friesen C, Debatin K-M. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer. 1998;76:105-114.
45. Fulda S, Scaffidi C, Pietsch T, Krammer PH, Peter ME, Debatin K-M. Activation of the CD95 (APO-1/Fas) pathway in drug- and γ-irradiation-induced apoptosis of brain tumor cells. Cell Death Differ. 1998;5:884-893.
46. Fulda S, Sieverts H, Friesen C, Herr I, Debatin K-M. The CD95(APO-1/Fas) system mediates drug induced apoptosis in neuroblastoma cells. Cancer Res. 1997;57:3823-3829.
47. Herr I, Wilhelm D, Bohler T, Angel P, Debatin K-M. JNK/SAPK activity is not sufficient for anticancer therapy-induced apoptosis involving CD95-L, TRAIL and TNF-α. Int J Cancer. 1999;80:417-424.
48. Leverkus M, Yaar M, Gilchrest BA. Fas/Fas ligand interaction contributes to UV-induced apoptosis in human keratinocytes. Exp Cell Res. 1997;232:255-262.
49. Mo Y-Y, Beck WT. DNA damage signals induction of Fas ligand in tumor cells. Mol Pharmacol. 1999;55:216-222.
50. Mueller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 1997;99:403-413.
51. Sheard MA, Vojtesek B, Janakova L, Kovarik J, Zaloudik J. Up-regulation of Fas (CD95) in human p53-wild-type cancer cells treated with ionizing radiation. Int J Cancer. 1997;73:757-762.
52. Vogt M, Bauer MKA, Ferrari D, Schulze-Osthoff K. Oxidative stress and hypoxia/reoxygenation trigger CD95 (APO-1/Fas) ligand expression in microglial cells. FEBS Lett. 1998;429:67-72.
53. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000;256:42-49.
54. McGahon AJ, Costa Pereira AP, Daly L, Cotter TG. Chemotherapeutic drug-induced apoptosis is independent of the Fas (APO-1/CD95) receptor/ligand system. Br J Haematol. 1998;101:539-547.
55. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel M-T. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst. 1997;89:783-789.
56. Friesen C, Fulda S, Debatin K-M. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia. 1997;11:1833-1841.
57. Landowski TH, Gleason-Guzman MC, Dalton WS. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood. 1997;89:1854-1861.
58. Los M, Herr I, Fulda S, Friesen C, Schulze-Osthoff K, Debatin K-M. Activation of ICE/Ced-3 proteases by anticancer drugs. Blood. 1997;90:3118-3129.
59. Aragane Y, Kulms D, Metze D, et al. Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L. J Cell Biol. 1998;140:171-182.
60. Micheau O, Solary E, Hammann A, Dimanche-Boitrel M-T. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem. 1999;274:7987-7992.
61. Rehemtulla A, Hamilton CA, Chinnaiyan AM, Dixit VM. Ultraviolet radiation-induced apoptosis is mediated by activation of CD95 (Fas/APO-1). J Biol Chem. 1997;272:25783-25786.
62. Eischen CM, Kottke TJ, Martins LM, et al. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood. 1997;3:935-943.
63. Villunger A, Egle A, Kos M, et al. Drug-induced apoptosis is associated with enhanced Fas (APO-1/CD95) ligand expression but occurs independently of Fas (APO-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res. 1997;57:3331-3334.
64. Newton K, Harris AW, Bath ML, Smith KGC, Strasser A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J. 1998;17:706-718.
65. Strasser A, Harris AW, Huang DCS, Krammer PH, Cory S. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J. 1995;14:6136-6147.
66. Glaser T, Wagenknecht B, Groscurth P, Krammer PH, Weller M. Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in malignant glioma cells. Oncogene. 1999;18:5044-5053.
67. Gamen S, Anel A, Lasierra P, et al. Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. FEBS Lett. 1997;41:360-364.
68. Fiedler P, Schaetzlein CE, Eibel H. Constitutive expression of FasL in thyrocytes [comment]. Science. 1998;279:2015.
69. Herr I, Posovsky C, Bohler T, Debatin K-M. mAb 33 from transduction laboratories specifically binds to human CD95-L. Cell Death Differ. 2000;7:129-130.
70. Papoff G, Stasi G, De Maria R, et al. Constitutive expression of FasL in thyrocytes [comment]. Science. 1998;279:2015.
71. Stokes TA, Rymaszewski M, Arscott PL, et al. Constitutive expression of FasL in thyrocytes [comment]. Science. 1998;279:2015.
72. Varfolomeev EE, Schuchmann M, Luria V, et al. Targeted disruption of the mouse caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity. 1998;9:267-276.
73. Yeh W-C, de la Pompa JL, McCurrach ME, et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science. 1998;279:1954-1958.
74. Hakem R, Hakem A, Duncan GS, et al. Differential requirement for caspase-9 in apoptotic pathways in vivo. Cell. 1998;94:339-352.
75. Kuida K, Haydar TF, Kuan C-Y, et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase-9. Cell. 1998;94:325-337.
76. Cecconi F, Alvarez-Bolado G, Meyer BI, Roth KA, Gruss P. Apaf1 (CED-4 homolog) regulates programmed cell death in mammalian development. Cell. 1998;94:727-737.
77. Yoshida H, Kong Y-Y, Yoshida R, et al. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell. 1998;94:739-750.
78. Jiang S, Song MJ, Shin E-C, Lee M-O, Kim SJ, Park JH. Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways. Hepatology. 1999;29:101-110.
79. Roy S, Nicholson DW. Cross-talk in cell death signaling. J Exp Med. 2000;192:F21-F25.
80. Fulda S, Meyer E, Debatin KM. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene. 2001;20:1063-1075.
81. Borner C, Monney L. Apoptosis without caspases: an inefficient molecular guillotine? Cell Death Diff. 1999;6:497-507.
82. Chautan M, Chazal G, Cecconi F, Gruss P, Golstein P. Interdigital cell death can occur through a necrotic and caspase-independent pathway. Curr Biol. 1999;9:967-970.
83. Kitanaka C, Kuchino Y. Caspase-independent programmed cell death with necrotic morphology. Cell Death Differ. 1999;6:508-515.
84. Miller TM, Moulder KL, Knudson CM, et al. Bax deletion further orders the cell death pathway in cerebellar granule cells and suggests a caspase-independent pathway to cell death. J Cell Biol. 1997;139:205-217.
85. Xiang J, Chao DT, Korsmeyer SJ. Bax-induced cell death may not require interleukin 1-converting enzyme-like proteases. Proc Natl Acad Sci U S A. 1996;93:14559-14563.
86. Kawahara A, Ohsawa Y, Matsumura H, Uchiyama Y, Nagata S. Caspase-independent cell killing by Fas-associated protein with death domain. J Cell Biol. 1998;143:1353-1360.
87. Vercammen D, Beyaert R, Denecker G, et al. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J Exp Med. 1998;187:1477-1485.
88. Schulze-Osthoff K, Krammer PH, Droege W. Divergent signaling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J. 1994;13:4587-4596.
89. Stoka V, Turk B, Schendel SL, et al. Lysosomal protease pathways to apoptosis. J Biol Chem. 2001;276:3149-3157.
90. Gao G, Dou P. N-terminal cleavage of bax by calpain generates a potent proapoptotic 18-κDa fragment that promotes Bcl-2-independent cytochrome c release and apoptotic cell death. J Cell Biochem. 2000;80:53-72.
91. Wolf BB, Goldstein JC, Stennicke HR, et al. Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation. Blood. 1999;94:1683-1692.
92. Wood DE, Thomas A, Devi LA, et al. Bax cleavage is mediated by calpain during drug-induced apoptosis. Oncogene. 1998;17:1096-1078.
93. Reddy RK, Jun L, Lee AS. The endoplasmic reticulum chaperone glycoprotein GRP94 with Ca2+-binding and antiapoptotic properties is a novel proteolytic target of calpain during etoposide-induced apoptosis. J Biol Chem. 1999;274:28476-28483.
94. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta. 1991;1072:129-157.
95. Leppä S, Bohmann D. Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene. 1999;18:6158-6162.
96. Davis R. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103:239-252.
97. Ip YT, Davis RJ. Signal transduction by the c-Jun N-terminal kinase (JNK) - from inflammation to development. Curr Opin Cell Biol. 1998;10:205-219.
98. Minden A, Karin M. Regulation and function of the JNK subgroup of MAP kinases. Biochim Biophys Acta. 1997;1333:85-104.
99. Weitzman JB. Quick guide. Jnk. Curr Biol. 2000;10:R290.
100. Chen Y-R, Meyer CF, Tan T-H. Persistent activation of c-Jun N-terminal kinase 1 (JNK1) in gradiation-induced apoptosis. J Biol Chem. 1996;271:631-634.
101. Chen Z, Seimiya H, Naito M, et al. ASK1 mediates apoptotic cell death induced by genotoxic stress. Oncogene. 1999;18:173-180.
102. Faris M, Latinis KM, Kempiak SJ, Koretzky GA, Nel A. Stress-induced Fas ligand expression in T cells is mediated through a MEK kinase 1-regulated response element in the Fas ligand promoter. Mol Cell Biol. 1998;18:5414-5424.
103. Goillot E, Raingeaud J, Ranger A, et al. Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Proc Natl Acad Sci U S A. 1994;94:3302-3307.
104. Herr I, Wilhelm D, Meyer E, Jeremias I, Angel P, Debatin K-M. JNK/SAPK activity contributes to TRAIL-induced apoptosis. Cell Death Differ. 1999;6:130-135.
105. Johnson NL, Gardner AM, Diener KM, et al. Signal transduction pathways regulated by mitogen-activated/extracellular response kinase kinase kinase induce cell death. J Biol Chem. 1996;271:3229-3237.
106. Minden A, Lin A, McMahon M, et al. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science. 1994;266:1719-1723.
107. Tournier C, Hess P, Yang DD, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science. 2000;288:870-874.
108. Verheij M, Bose R, Hua Lin X, et al. Requirement for ceramide initiated JNK/SAPK signalling in stress-induced apoptosis. Nature. 1996;380:75-79.
109. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995;270:1326-1331.
110. Yang DD, Kuan CY, Whitmarsh AJ, et al. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature. 1997;389:865-870.
111. Yang X, Khosravi-Far R, Chang HY, Baltimore D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell. 1997;89:1067-1076.
112. Zanke BW, Boudreau K, Rubie E, et al. The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat. Curr Biol. 1996;6:606-613.
113. Nishina H, Fischer KD, Radvanyl L, et al. Stress-signalling protects thymocytes from apoptosis mediated by CD95 and CD3. Nature. 1997;385:350-353.
114. Liu Z-G, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell. 1996;87:565-576.
115. Natoli G, Costanzo A, Ianni A, et al. Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway. Science. 1997;275:200-203.
116. Kuan CY, Yang DD, Samanta Roy DR, Davis RJ, Rakic P, Flavell RA. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron. 1999;22:667-676.
117. Sabapathy K, Jochum W, Hochedlinger K, Chang L, Karin M, Wagner EF. Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2. Mech Dev. 1999;89:115-124.
118. Behrens A, Sibilia M, Wagner EF. Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat Gen. 1999;21:326-329.
119. Kolbus A, Herr I, Schreiber M, Debatin K-M, Wagner EF, Angel P. c-Jun dependent induction of CD95-L expression is a rate-limiting step in the induction of apoptosis by alkylating agents. Mol Cell Biol. 2000;20:575-582.
120. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboudi A, Green DR. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-κB and AP-1. Mol Cell. 1998;1:543-551.
121. Faris M, Kokot N, Latinis K, et al. The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression. J Immunol. 1998;160:134-144.
122. Harwood FG, Kasibhatla S, Petak I, Vernes R, Green DR, Houghton JA. Regulation of FasL by NF-κB and AP-1 in Fas-dependent thymineless death of human colon carcinoma cells. J Biol Chem. 2000;275:10023-10029.
123. Le-Niculescu H, Bonfoco E, Kasuya Y, Claret F-X, Green DR, Karin M. Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol Cell Biol. 1999;19:751-763.
124. Matsui K, Xiao S, Fine A, Ju S-T. Role of activator protein-1 in TCR-mediated regulation of the murine fasl promoter. J Immunol. 2000;164:3002-3008.
125. Tsai ET, Jain J, Pesavento PA, Rao A, Goldfeld AE. Tumor necrosis factor α gene regulation in activated T cells involves ATF-2 and NFAT. Mol Cell Biol. 1996;16:459-467.
126. Zagariya A, Mungre S, Lovis R, et al. Tumor necrosis factor alpha gene regulation: enhancement of C/EBPβ-induced activation by c-Jun. Mol Cell Biol. 1998;18:2815-2824.
127. 2-terminal kinase. J Exp Med. 2000;191:1017-1029.
128. Lee H, Arsura M, Wu M, Duyao M, Buckler AJ, Sonenshein GE. Role of Rel-related factors in control of c-myc gene transcription in receptor-mediated apoptosis of the murine B cell WEHI 231 line. J Exp Med. 1995;181:1169-1177.
129. Fuchs SY, Adler V, Buschmann T, et al. JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev. 1998;12:2658-2663.
130. Fuchs SY, Adler V, Pincus MR, Ronai Z. MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci U S A. 1998;95:10541-10546.
131. Schreiber M, Kolbus A, Piu F, et al. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev. 1999;13:607-613.
132. Noguchi K, Kitanaka C, Yamana H, Kokubu A, Mochizuki T, Kuchino Y. Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase. J Biol Chem. 1999;274:32580-32587.
133. Hatai T, Matsuzawa A, Inoshita S, et al. Execution of ASK1-induced apoptosis by the mitochondria-dependent caspase activation. J Biol Chem. 2000;275:26576-26581.
134. L in response to DNA damage. J Biol Chem. 2000;275:322-327.
135. Park J, Kim I, Young JO, Lee K-W, Han P-L, Choi E-J. Activation of c-Jun N-terminal kinase antagonizes an anti-apoptotic action of bcl-2. J Biol Chem. 1997;272:16725-16728.
136. Wang X-Z, Lawson B, Brewer JW, et al. Signals from the stressed endoplasmic reticulum induce C/EBP-homologous protein (CHOP/GADD153). Mol Cell Biol. 1996;16:4273-4280.
137. Kaufman RJ. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev. 1999;13:1211-1233.
138. Zinszner H, Kuroda M, Wang XZ, et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev. 1998;12:982-995.
139. Baichwal VR, Bauerle PA. Activate NF-κB or die? Curr Biol. 1997;7:R94-R96.
140. Nakagawa T, Zhu H, Morishima N, et al. Caspase-12-mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature. 2000;403:98-103.
141. Xu Q, Reed JC. Bax inhibitor-1, a mammalian apoptosis suppressor identified by functional screening in yeast. Mol Cell. 1998;1:337-346.
142. L cooperatively associates with the Bap31 complex in the endoplasmic reticulum, dependent on procaspase-8 and Ced-4 adaptor. J Biol Chem. 1998;273:3140-3143.
143. Nguyen M, Breckenridge DG, Ducret A, Shore GC. Caspase-resistant BAP31 inhibits Fas-mediated apoptotic membrane fragmentation and release of cytochrome c from mitochondria. Mol Cell Biol. 2000;20:6731-6740.
144. Torgler CN, de Tiani M, Raven T, Aubry J-P, Brown R, Meldrum E. Expression of bak in S. pombe results in a lethality mediated through interaction with the calnexin homologue Cnx1. Cell Death Differ. 1997;4:263-271.
145. Kuo TH, Kim HR, Zhu L, Yu L, Lin HM, Tsang W. Modulation of endoplasmic reticulum calcium pump by Bcl-2. Oncogene. 1998;17:1903-1910.
146. L and Bcl-2 on endoplasmic reticulum and reduces their anti-apoptotic activity. Oncogene 2000;19:5736-5746.
147. Häcki J, Egger L, Monney L, et al. Apoptotic crosstalk between the endoplasmic reticulum and mitochondria controlled by Bcl-2. Oncogene. 2000;19:2286-2295.
148. Nakamura K, Bossy-Wetzel E, Burns K, et al. Changes in endoplasmic reticulum luminal environment affect cell sensitivity to apoptosis. J Cell Biol. 2000;150:731-740.
149. Kyriakis JM, Banerjee P, Nikolakaki E, et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature. 1994;369:156-160.
150. Urano F, Wang XZ, Bertolotti A, et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science. 2000;287:664-666.
151. 2-terminal kinase activity, and apoptosis. Mol Cell Biol. 1999;19:5659-5674.
152. Levine JL. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
153. Venot C, Maratrat M, Dureuil C, Conseiller E, Bracco L, Debussche L. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J. 1998;17:4668-4679.
154. Walker KK, Levine AJ. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A. 1996;93:15335-15340.
155. Zhu J, Zhou W, Jiang J, Cheng X. Identification of a novel p53 functional domain that is necessary for mediating apoptosis. J Biol Chem. 1998;273:13030-13036.
156. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 1998;12:2973-2983.
157. Prives C. Signaling to p53: breaking the MDM2-p53 circuit. Cell. 1998;95:5-8.
158. Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren M. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev. 1995;9:2170-2183.
159. Morgenbesser SD, Williams BO, Jacks T, De-Pinho RA. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature. 1994;371:72-74.
160. Bing A, Dou QP. Cleavage of retinoblastoma protein during apoptosis: an interleukin 1 beta-converting enzyme-like protease as candidate. Cancer Res. 1996;56:438-442.
161. Erhardt P, Tomaselli KJ, Cooper GM. Identification of the MDM2 oncoprotein as a substrate for CPP32-like apoptotic proteases. J Biol Chem. 1997;272:15049-15052.
162. Janicke RU, Walker PA, Lin XY, Porter AG. Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. EMBO J. 1996;15:6969-6978.
163. Brodsky MH, Nordstrom W, Tsang G, Kwan E, Rubin GM, Abrams JM. Drosophila p53 binds a damage response element at the reaper locus. Cell. 2000;101:103-113.
164. Mueller M, Wilder S, Bannasch D, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 1998;188:2033-2045.
165. Oda K, Arakawa H, Tanaka T, et al. p53AIP1, a potential mediator of p53-dependent apoptosls, and its regulation by Ser-46-phosphorylated p53. Cell. 2000;102:849-862.
166. Owen-Schaub LB, Zhang W, Cusack JC, et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol. 1995;6:3032-3040.
167. Sheikh MS, Burns TF, Huang Y, et al. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res. 1998;15:1593-1598.
168. Thomas A, Giesler T, White E. p53 mediates Bcl-2 phosphorylation and apoptosis via activation of the Cdc42/JNK1 pathway. Oncogene. 2000;19:5259-5269.
169. Wu GS, Burns TF, McDonald ER III, et al. Induction of TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest. Oncogene. 1999;11:6411-6418.
170. Soengas MS, Alarcon RM, Yoshida H, et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science. 1999;284:156-159.
171. Bennett M, MacDonald K, Chan SW, Luzio JP, Simari R, Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science. 1998;282:290-293.
172. Munsch D, Watanabe-Fukunaga R, Bourdon J-C, et al. Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis. J Biol Chem. 2000;275:3867-3872.
173. Li P-F, Dietz R, von Harsdorf R. p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by bcl-2. EMBO J. 1999;18:6027-6036.
174. Newton K, Strasser A. Ionizing radiation and chemotherapeutic drugs induce apoptosis in lymphocytes in the absence of Fas or FADD/MORT1 signaling: implications for cancer therapy. J Exp Med. 2000;191:195-200.
175. O'Connor L, Harris AW, Strasser A. CD95 (Fas/APO-1) and p53 signal apoptosis independently in diverse cell types. Cancer Res. 2000;60:1217-1220.
176. Johnson TM, Yu ZX, Ferrans VJ, Lowenstein RA, Finkel T. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc Natl Acad Sci U S A. 1996;93:11848-11852.
177. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature. 1997;389:300-305.
178. Ding HF, McGill G, Rowan S, Schmaltz C, Shimamura A, Fisher DE. Oncogene-dependent regulation of caspase activation by p53 protein in a cell-free system. J Biol Chem. 1998;273:28378-29283.
179. Ravi R, Bedi GC, Engstrom LW, et al. Regulation of death receptor expression and TRAIL/APO2L-induced apoptosis by NF-κB. Nat Cell Biol. 2001;3:409-416.
180. Baeuerle PA, Baltimore D. NF-κB: ten years after. Cell. 1996;87:13-20.
181. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-κB/IκB family: intimate tales of association and dissociation. Genes Dev. 1995;9:2723-2735.
182. Karin M. How NF-κB is activated: the role of the IκB kinase (IKK) complex. Oncogene. 1999;18:6867-6874.
183. Abbadie C, Kabrun N, Bouali F, et al. High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro. Cell. 1993;75:899-912.
184. Huguet C, Enrietto P, Vandenbunder B, Abbadie C. c-Rel: a multifunctional transcription factor? Cell Death Differ. 1994;1:71-76.
185. 1/S-phase transition. Mol Cell Biol. 1997;17:6526-6536.
186. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-alpha-induced cell death. Science. 1996;274:782-784.
187. Li Q, Estepa G, Memet S, Israel A, Verma IM. Complete lack of NF-κB activity in IKK1 and IKK2 double-deficient mice: additional defect in neurulation. Genes Dev. 2000;14:1729-1733.
188. Grossmann M, Metcalf D, Merryfull J, Beg A, Baltimore D, Gerondakis S. The combined absence of the transcription factors Rel and RelA leads to multiple hemopoietic cell defects. Proc Natl Acad Sci U S A. 1999;96:11848-11853.
189. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin K-M. Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells. Blood. 1998;91:4624-4631.
190. Wang C-Y, Mayo W, Baldwin AS Jr. TNF-α and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science. 1996;274:784-787.
191. Wu M, Lee H, Bellas RE, et al. Inhibition of NF- κB/Rel induces apoptosis of murine B cells. EMBO J. 1996;15:4682-4690.
192. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene. 1999;18:6853-6866.
193. Wang C-Y, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281:1680-1683.
194. Grigoridis G, Zhan Y, Grumont RJ, et al. The Rel subunit of NF-κB-like transcription factors is a positive and negative regulator of macrophage gene expression: distinct roles for Rel in different macrophage populations. EMBO J. 1996;15:7099-7107.
195. Mannick JB, Miao XQ, Stamler JS. Nitric oxide inhibits Fas-induced apoptosis. J Biol Chem. 1997;72:24125-24128.
196. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-κB transcription factors. Oncogene. 1999;18:6910-6924.
197. Chan H, Bartos DP, Owen-Schaub LB. Activation-dependent transcriptional regulation of the human fas promoter requires NF-κB p50-p65 recruitment. Mol Cell Biol. 1999;19:2098-2108.
198. Kasibhatla S, Genestier L, Green DR. Regulation of Fas-ligand expression during activation-induced cell death in T lymphocytes via nuclear
199. Rivera-Walsh I, Cvijic ME, Xiao G, Sun S-C. The NF-κ B signaling pathway is not required for Fas ligand gene induction but mediates protection from activation-induced cell death. J Biol Chem. 2000;275:25222-25230.
200. Schulze-Osthoff K, Stroh C. Induced proximity model attracts NF-κB researchers. Cell Death Differ. 2000;7:1025-1026.
201. Tak PP, Firestein GS. NF-κB: a key role in inflammatory diseases. J Clin Invest. 2001;107:7-11.
202. Basu S, Kolesnick R. Stress signals for apoptosis: ceramide and c-Jun kinase. Oncogene. 1998;17:3277-3285.
203. Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science. 1996;274:1866-1859.
204. Hannun YA, Luberto C. Ceramide in the eukaryotic stress response. Trends Cell Biol. 2000;10:73-80.
205. Kolesnick R, Fuks Z. Ceramide: a signal for apoptosis or mitogenesis? J Exp Med. 1995;181:1949-1952.
206. Malisan F, Testi R. Lipid signaling in CD95-mediated apoptosis. FEBS Lett. 1999;452:100-103.
207. Testi R. Sphingomyelin breakdown and cell fate. Trends Biochem Sci. 1996;21:468-471.
208. Cuvillier O, Pirianov G, Kleuser B, et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature. 1996;381:800-803.
209. Van Brocklyn JR, Cuvillier O, Olivera A, Spiegel S. Sphingosine-1-phosphate: a lipid second messenger regulating cell growth and survival. J Liposome Res. 1998;8:135-145.
210. Bourbon NA, Yun J, Kester M. Ceramide directly activates protein kinase C ζ to regulate a stress-activated protein kinase signaling complex. J Biol Chem. 2000;275:35617-35623.
211. Herr I, Martin-Villalba A, Kurz E, et al. FK506 prevents stroke-induced generation of ceramide and apoptosis signaling. Brain Res. 1999;826:210-219.
212. Herr I, Wilhelm D, Bohler T, Angel P, Debatin K-M. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J. 1997;16:6200-6208.
213. Basu S, Bayoumy S, Zhang Y, Lozano J, Kolesnick R. BAD enables ceramide to signal apoptosis via Ras and Raf-1. J Biol Chem. 1998;273:30419-30426.
214. Quillet-Mary A, Jaffrezou JP, Mansat V, Bordier C, Naval J, Laurent G. Implication of mitochondrial hydrogen peroxide gereration in ceramide-induced apoptosis. J Biol Chem. 1997;272:21388-21395.
215. Susin SA, Zamzami N, Castedo M, et al. The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced apoptosis. J Exp Med. 1997;186:25-37.
216. De Maria R, Lenti L, Malisan F, et al. Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis. Science. 1997;277:1652-1655.
217. Chmura JS, Nodzenski E, Beckett MA, Kufe DW, Quintans J, Weichselbaum RR. Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res. 1997;57:1270-1275.
218. Michael JM, Lavin MF, Watters DJ. Resistance to radiation-induced apoptosis in Burkitt's lymphoma cells is associated with defective ceramide signaling. Cahcer Res. 1997;57:3600-3605.
219. Santana P, Pena LA, Haimovitz-Friedman A, et al. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell. 1996;86:189-199.
220. Chinnaiyan AM, Tepper CG, Seldin MF, et al. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem. 1996;271:4961-4965.
221. Mizushima N, Koike R, Kohsaka H, et al. Ceramide induces apoptosis via CPP32 activation. FEBS Lett. 1996;395:267-271.
222. Suzuki A, Iwasaki M, Kato M, Wagai N. Sequential operation of ceramide synthesis and ICE cascade in CPT-11-initiated apoptotic death signaling. Exp Cell Res. 1997;233:41-47.
223. Brenner B, Ferlinz K, Grassme H, et al. Fas/CD95/APO-1 activates the acidic sphingomyelinase via caspases. Cell Death Differ. 1998;5:29-37.
224. Gamen S, Marzo I, Anel A, Pineiro A, Naval J. CPP32 inhibition prevents Fas-induced ceramide generation and apoptosis in human cells. FEBS Lett. 1996;390:232-237.
225. Pronk GJ, Ramer K, Amiri P, Willians LT. Requirement of an ICE-like protease for induction of apoptosis and ceramide generation by REAPER. Science. 1996;271:808-810.
226. Sillence DJ, Allan D. Evidence against an early signaling role for ceramide in Fas-mediated apoptosis. Biochem J. 1997;324:29-32.
227. Watts JD, Gu M, Polverino AJ, Patterson SD, Aebersold R. Fas-induced apoptosis of T cells occurs independently of ceramide generation. Proc Natl Acad Sci U S A. 1997;94:7292-7296.
228. Farber S, Diamon LK, Mercer RD, Sylvester RFJ, Wolff JA. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteoylglutamic acid (amiopterin). N Engl J Med. 1948;238:787-793.
229. Does cancer therapy trigger cell suicide? [editorial]. Science. 1999;286:2256-2258.
230. Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med. 2000;6:1029-1035.
231. Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene. 1999;18:7644-7655.
232. Vousden KH. p53: death star. Cell. 2000;103:691-694.